MDMA-induced impairment in primates: Antagonism by a selective norepinephrine or serotonin, but not by a dopamine/norepinephrine transport inhibitor

Journal of Psychopharmacology

Volumn 22, Issue 2, 2008, Pages 187-202

  Verrico, Christopher D ^a   Lynch, Laurie ^a   Fahey, Michele A ^a   Fryer, Ashley Kay ^a   Miller, Gregory M ^a   Madras, Bertha K ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Aversion; Cognition; Impairment; Inhibitor; MDMA; Monoamine transporter; Rhesus monkey

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; CITALOPRAM; DESIPRAMINE; DOPAMINE TRANSPORTER; DOPAMINE UPTAKE INHIBITOR; FLUOXETINE; MAZINDOL; METHYLPHENIDATE; MONOAMINE; NORADRENALIN TRANSPORTER; NORADRENALIN UPTAKE INHIBITOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; TRITIUM;

ANIMAL EXPERIMENT; ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG DOSE COMPARISON; HUMAN; HUMAN CELL; IN VITRO STUDY; LEARNING; MACACA; MALE; MANDIBLE; NONHUMAN; PRIMATE; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; SLEEP; TASK PERFORMANCE;

ADMINISTRATION, ORAL; ANIMALS; APPETITIVE BEHAVIOR; ASSOCIATION LEARNING; CELL LINE; CITALOPRAM; DESIPRAMINE; DISCRIMINATION LEARNING; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; INJECTIONS, INTRAMUSCULAR; MACACA FASCICULARIS; MALE; MENTAL RECALL; METHYLPHENIDATE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; REVERSAL LEARNING; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; STEREOTYPED BEHAVIOR;

EID: 40049084030     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881107083639     Document Type: Article

References (43)

1. Battaglia G., Brooks B.P., Kulsakdinun C., De Souza E.B. (1988) Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. Eur J Pharmacol 149: 159 - 163
2. Buchert R., Thomasius R., Wilke F., Petersen K., Nebeling B., Obrocki J., Schulze O., Schmidt U., Clausen M. (2004) A voxel-based PET investigation of the long-term effects of 'Ecstasy' consumption on brain serotonin transporters. Am J Psychiatry 161: 1181 - 1189
3. Cami J., Farre M., Mas M., Roset P.N., Poudevida S., Mas A., San L., de la Torre R. (2000). Human pharmacology of 3,4-methylenedioxymethamphetamine ('ecstasy'): psychomotor performance and subjective effects. J Clin Psychopharmacol 20: 455 - 466
4. Curran H.V., Travill R.A. (1997) Mood and cognitive effects of ±3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'). week-end 'high' followed by mid-week low. Addiction 92: 821 - 831
5. Dafters R.I. (2005). Chronic ecstasy (MDMA) use is associated with deficits in task-switching but not inhibition or memory updating executive functions. Drug Alcohol Depend 83 (2). 181 - 184
6. Downing J. (1986) The psychological and physiological effects of MDMA on normal volunteers. J Psychoactive Drugs 8 (4). 335 - 340
7. Farre M., de la Torre R., Mathuna B.O., Roset P.N., Peiro A.M., Torrens M., Ortuno J., Pujadas M., Cami J. (2004) Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics. Psychopharmacology (Berl) 173: 364 - 375
8. Frederick D.L., Paule M.G. (1997) Effects of MDMA on complex brain function in laboratory animals. Neurosci Biobehav Rev 21: 67 - 78
9. Gouzoulis-Mayfrank E., Fischermann T., Rezk M., Thimm B., Hensen G., Daumann J. (2005) Memory performance in polyvalent MDMA (ecstasy) users who continue or discontinue MDMA use. Drug Alcohol Depend 78: 317 - 323
10. Green A.R., Mechan A.O., Elliott J.M., O'Shea E., Colado M.I. (2003) The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'). Pharmacol Rev 55: 463 - 508
11. Goulet M., Madras B.K. (2000) D(1) dopamine receptor agonists are more effective in alleviating advanced than mild parkinsonism in 1-methyl-4-phenyl-1, 2,3, 6-tetrahydropyridine-treated monkeys. J Pharmacol Exp Ther 292 (2). 714 - 724
12. Halpern J.H., Pope H.G., Jr., Sherwood A.R., Barry S., Hudson J.I., Yurgelun-Todd D. (2004) Residual neuropsychological effects of illicit 3,4-methylenedioxymethamphetamine (MDMA) in individuals with minimal exposure to other drugs. Drug Alcohol Depend 75: 135 - 47
13. Hansen J.P., Riddle E.L., Sandoval V., Brown J.M., Gibb J.W., Hanson G.R., Fleckenstein A.E. (2002) Methylenedioxymethamphetamine decreases plasmalemmal and vesicular DA transport: mechanisms and implications for neurotoxicity. J Pharmacol Exp Ther 300: 1093 - 1100
14. Jentsch J.D., Olausson P., De La Garza R. 2nd, Taylor J.R. (2002) Impairments of reversal learning and response perseveration after repeated, intermittent cocaine administrations to monkeys. Neuropsychopharmacology 26: 183 - 190
15. Kuypers K.P., Ramaekers J.G. (2005) Transient memory impairment after acute dose of 75 mg 3.4-Methylene-dioxymethamphetamine. J Psychopharmacol 19: 633 - 639
16. Liechti M.E., Vollenweider F.X. (2000) The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine ('Ecstasy') in healthy volunteers. J Psychopharmacol 14: 269 - 274
17. Liechti M.E., Gamma A., Vollenweider F.X. (2001) Gender differences in the subjective effects of MDMA. Psychopharmacology (Berl) 154: 161 - 168
18. Liechti M.E., Baumann C., Gamma A., Vollenweider F.X. (2000) Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') are attenuated by the serotonin uptake inhibitor citalopram Neuropsychopharmacology 22: 513 - 521
19. Lile J.A., Ross J.T., Nader M.A. (2005) A comparison of the reinforcing efficacy of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') with cocaine in rhesus monkeys. Drug Alcohol Depend 78: 135 - 140
20. Madras B.K., Miller G.M., Fischman A.J. (2005) The dopamine transporter and attention-deficit/hyperactivity disorder. Biol Psychiatry 57: 1397 - 1409
21. Madras B.K., Xie Z., Lin Z., Jassen A., Panas H., Lynch L., Johnson R., Livni E., Spencer T.J., Bonab A.A., Miller G.M., Fischman A.J. (2006) Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. J Pharmacol Exp Ther 319 (2). 561 - 569
22. McCann U.D., Ricaurte G.A. (1991) Lasting neuropsychiatric sequelae of (+/-) methylenedioxymethamphetamine ('ecstasy') in recreational users. J Clin Psychopharmacol 11: 302 - 305
23. McCann U.D., Ridenour A., Shaham Y., Ricaurte G.A. (1994) Serotonin neurotoxicity after (+/-)3,4-methylenedioxymethamphetamine (MDMA; 'Ecstasy'). a controlled study in humans. Neuropsychopharmacology 10: 129 - 138
24. McCann U.D., Mertl M., Eligulashvili V., Ricaurte G.A. (1999) Cognitive performance in (+/-) 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') users: a controlled study. Psychopharmacology (Berl) 143: 417 - 425
25. Mechan A., Yuan J., Hatzidimitriou G., Irvine R.J., McCann U.D., Ricaurte G.A. (2005) Pharmacokinetic profile of single and repeated oral doses of mdma in squirrel monkeys: relationship to lasting effects on brain serotonin neurons. Neuropsychopharmacology 31: 339 - 350
26. Miller G.M., Verrico C.D., Jassen A., Konar M., Yang H., Panas H., Bahn M., Johnson R., Madras B.K. (2005) Primate trace amine receptor 1 modulation by the dopamine transporter. J Pharmacol Exp Ther 313: 983 - 994
27. Miyake A., Friedman N.P., Emerson M.J., Witzki A.H., Howerter A., Wager T.D. (2000) The unity and diversity of executive functions and their contributions to complex 'Frontal Lobe' tasks: a latent variable analysis. Cognit Psychol 41: 49 - 100
28. Morgan M.J., Impallomeni L.C., Pirona A., Rogers R.D. (2005) Elevated impulsivity and impaired decision-making in abstinent ecstasy (MDMA) users compared to polydrug and drug-naive controls. Neuropsychopharmacology 31: 1562 - 1573
29. Pacifici R., Pichini S., Zuccaro P., Farre M., Segura M., Ortuno J., Di Carlo S., Bacosi A., Roset P.N., Segura J., de la Torre R. (2004) Paroxetine inhibits acute effects of 3,4-methylenedioxymethamphetamine on the immune system in humans. J Pharmacol Exp Ther 309: 285 - 292
30. Parrott A.C. (2001) Human psychopharmacology of ecstasy (MDMA). a review of 15 years of empirical research. Hum Psychopharmacol 16: 557 - 577
31. Parrott A.C., Lasky J. (1998) Ecstasy (MDMA) effects upon mood and cognition: before, during and after a saturday night dance. Psychopharmacology (Berl) 139: 261 - 268
32. Peroutka S.J., Newman H., Harris H. (1988) Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users Neuropsychopharmacology 1: 273 - 277
33. Reneman L., Lavalaye J., Schmand B., de Wolff F.A., van den Brink W., den Heeten G.J., Booij J. (2001) Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-methylenedioxymethamphetamine (MDMA or 'ecstasy'). preliminary findings. Arch Gen Psychiatry 58: 901 - 906
34. Ricaurte G.A., DeLanney L.E., Irwin I., Langston J.W. (1988) Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration. Brain Res 446: 165 - 168
35. Sulzer D., Sonders M.S., Poulsen N.W., Galli A. (2005) Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol 75: 406 - 433
36. Taffe M.A., Weed M.R., Davis S., Huitron-Resendiz S., Schroeder R., Parsons L.H., Henriksen S.J., Gold L.H. (2001). Functional consequences of repeated (+/-) 3,4-methylenedioxymethamphetamine (MDMA) treatment in rhesus monkeys. Neuropsychopharmacology 24: 230 - 239
37. Taffe M.A., Davis S.A., Yuan J., Schroeder R., Hatzidimitriou G., Parsons L.H., Ricaurte G.A., Gold L.H. (2002) Cognitive performance of MDMAtreated rhesus monkeys: sensitivity to serotonergic challenge. Neuropsychopharmacology 27: 993 - 1005
38. Taylor J.R., Elsworth J.D., Roth R.H., Sladek J.R., Jr., Redmond D.E. Jr (1990) Cognitive and motor deficits in the acquisition of an object retrieval/detour task in MPTP-treated monkeys. Brain 113 (Pt 3). 617 - 637
39. Verheyden S.L., Henry J.A., Curran H.V. (2003) Acute, sub-acute and long-term subjective consequences of 'ecstasy' (MDMA) consumption in 430 regular users. Hum Psychopharmacol 18: 507 - 517
40. Verrico C., Miller G.M., Madras B.K. (2007) (Ecstasy) and Human Dopamine, norepinephrine and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment. Psychopharmacology (Berl) 189 (4). 489 - 503
41. Vollenweider F.X., Liechti M.E., Paulus M.P. (2005) MDMA affects both error-rate dependent and independent aspects of decision-making in a two-choice prediction task. J Psychopharmacol 19: 366 - 374
42. Vollenweider F.X., Gamma A., Liechti M., Huber T. (1998) Psychological and cardiovascular effects and short-term sequelae of MDMA ('ecstasy') in MDMA-naive healthy volunteers. Neuropsychopharmacology 19: 241 - 251
43. von Geusau N.A., Stalenhoef P., Huizinga M., Snel J., Ridderinkhof K.R. (2004) Impaired executive function in male MDMA ('ecstasy') users. Psychopharmacology (Berl) 175: 331 - 341